Scorr-Insert
X

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibutilide

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Premier Intermediates Pvt.Ltd.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 19, 2020

            Details:

            Premier’s ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempedoic Acid,Ezetimibe

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Otsuka Pharmaceutical

            Deal Size: $510.0 million Upfront Cash: $60.0 million

            Deal Type: Collaboration April 20, 2020

            Details:

            The collaboration advances the commitment of both companies to provide cost-effective, oral, once-daily, non-statin LDL-cholesterol lowering medicines for hypercholesterolemia patients in Japan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bempedoic Acid,Ezetimibe

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            Details:

            NUSTENDI is approved for patients who require additional Ldl-Cholesterol lowering on a background statin, other lipid-lowering therapies, or considered statin intolerant.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tirofiban Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hong Kong Teson Pharma

            Deal Size: $3.5 million Upfront Cash: $3.0 million

            Deal Type: Agreement March 10, 2020

            Details:

            The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Alprostadil

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Advanz Pharma

            Deal Size: $98.0 million Upfront Cash: $84.0 million

            Deal Type: Agreement March 06, 2020

            Details:

            The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sacubitril valsartan sodium hydrate

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Otsuka Chemical Co Ltd

            Deal Size: Undisclosed Upfront Cash: $90.0 million

            Deal Type: Agreement March 02, 2020

            Details:

            Under the terms of this agreement, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Troxerutin

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: STADA Production Ireland Ltd., trading as Suir Pharma Ireland

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition February 24, 2020

            Details:

            The transaction represents 15 brands including Venoruton, for venous treatment; Coldrex cold remedy; Cetebe vitamin C supplements; Mebucaine sore throat range and Tavegyl allergy brand.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Propranolol

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATNAHS PHARMA UK LIMITED

            Deal Size: $390.0 million Upfront Cash: $350.0 million

            Deal Type: Divestment January 27, 2020

            Details:

            AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Evolocumab

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Amgen Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 23, 2020

            Details:

            Under the acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Phenylephrine HCl

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xellia Pharmaceuticals ApS

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 21, 2020

            Details:

            Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.

            PharmaCompass